The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tract, by making optimal use of the Nanofitin (Nf) protein scaffold. Nf based drugs will progress through routes not travelled by antibodies while interacting with targets not modulated by chemical compounds.Existing Nf hits against validated targets will progre ...